Form 4: Axsome Therapeutics GC Receives Performance Stock Units
Statement of Changes in Beneficial Ownership
Axsome Therapeutics General Counsel Hunter R. Murdock was granted 7,224 performance stock units tied to commercial milestones.
Summary
- General Counsel Hunter R. Murdock received a grant of 7,224 performance stock units (PSUs) on April 21, 2026.
- Each PSU represents a contingent right to receive one share of Axsome Therapeutics common stock.
- Vesting of these units is contingent upon the achievement of specific sales and commercial launch milestones.
- The reporting person must maintain continued service with the company to satisfy vesting requirements.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not materially alter the company's financial position.
Positives
- Aligns executive compensation with the company's commercial success and sales performance.
- Incentivizes long-term retention of key legal leadership.
Negatives
- Increases potential future dilution for existing shareholders upon the vesting and conversion of these units.
Risks
- Vesting is subject to commercial milestones which may not be achieved.
- Continued service requirement creates dependency on key personnel retention.
Future Outlook
The vesting of the granted units is tied to future sales and commercial launch milestones, indicating management's focus on scaling commercial operations.
Industry Context
StockSavvy.ai notes that performance-based equity grants are standard practice in the biotechnology sector to align executive incentives with the successful commercialization of drug pipelines.
Comparison to Industry Standards
- The use of PSUs tied to commercial milestones is consistent with compensation structures at peer mid-cap biopharmaceutical companies.
- Grant sizes for legal counsel are generally aligned with industry benchmarks for executive compensation packages.
Stakeholder Impact
- Shareholders may experience minor dilution if milestones are met and shares are issued.
Next Steps
- Monitoring of commercial milestones to determine future vesting of the granted units.
Key Dates
| Date | Description |
|---|---|
| 04/21/2026 | Date of the transaction involving the grant of performance stock units. |
| 04/23/2026 | Date the Form 4 was signed and filed with the SEC. |
Keywords
Axsome Therapeutics, AXSM, Insider Transaction, Performance Stock Units, Executive Compensation, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.